MedPath

Effect of combination therapy of Pegylated interferon- Alpha 2a, Sofosbuvir and Ribavirin for 12 weeks versus combination of Sofosbuvir and Ribavirin for 24 weeks on viral loads in HCV Genotype 3 chronic hepatitis & compensated cirrhosis patients

Not Applicable
Recruiting
Conditions
HCV genotype 3 related chronic hepatitis & compensated cirrhosis
Registration Number
SLCTR/2017/007
Lead Sponsor
Department of Hepatology Bangabandhu Sheikh Mujib Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

1. Age more than 18 years
2. Hepatitis C Virus (HCV) genotype 3
3. Chronic hepatitis/ Compensated Cirrhosis
4. Detectable HCV RNA in blood
5. Platelet count >90,000 /cmm

Exclusion Criteria

1. Decompensated cirrhosis
2. Co-infected with Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV)
3. Hepatocellular carcinoma
4. Pregnancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.